Influence of atorvastatin in different doses on major adverse cardiovascular events after percutaneous coronary intervention
WANG Xian-li
LIAN Qiu-fang
WANG Ya-ning
LI Xue-jie
LI Yan
WANG Xuan
Abstract：Objective To investigate the influence of atorvastatin in different doses on blood fat and major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI).Methods The patients with unstable angina pectoris (UAP) were chosen (n=120) from Jun. 2012 to Jan. 2014, and randomly divided into 40-mg group (n=62, male 32, female 30 and average age=52.10±10.55) treated with 40 mg atorvastatin and 20-mg group (n=58, male 30, female 28 and average age=51.09±9.54) treated with 20 mg atorvastatin before PCI, and continuously given atorvastatin after PCI. The levels of TC, LDL-C, TG and HDL-C, and incidence of MACE and adverse reactions were compared in 2 groups before, 1 m and 6 m after treatment.Results The levels of TC, LDL-C and TG decreased in 2 groups 1 m and 6 m after PCI (allP<0.05). The level of TC decreased 6 m after PCI, and levels of LDL-C and TG decreased 1 m and 6 m after PCI in 40-mg group compared with 20-mg group (allP<0.05). The incidence of MACE was 8.1% in 40-mg group and 13.8% in 20-mg group within 6 m after PCI (P<0.05). There were 2 patients with abnormal liver function in 40-mg group and 1 in 20-mg group, and there was no case of rhabdomyolysis or other adverse reactions observed in 2 group (P>0.05).Conclusion Atorvastatin can reduce the level of blood fat in UAP patients after PCI, and the incidence of MACE decreases in patients with 40 mg atorvastatin than that in those with 20 mg atorvastatin.
Keywords：AtorvastatinAfter percutaneous coronary interventionMajor adverse cardiovascular events
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 679-681 )